跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
BAMLANIVIMAB - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
BAMLANIVIMAB
Authorized
STANDARD
BAMLANIVIMAB
eli lilly canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
6961cb2a408bfb4a
Company
eli lilly canada inc
Type
Standard
Approval Details
Approval Id
6961cb2a408bfb4a
Drug Approval Canada Name
BAMLANIVIMAB
Product Name
BAMLANIVIMAB
Status
Cancelled Post Market
Status Date
2023-02-13
Original Market Date
2020-12-24
Din
02508176
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Intravenous
Schedule
COVID-19 - IO - Authorization , Schedule D , Prescription
Ahfs
08:18.24
Atc Original
J06B IMMUNOGLOBULINS
Atc Name
j 06 b
Aig Number
0162600002
Company Name
eli lilly canada inc
Company Address
SUITE 900, Exchange Tower, 130 King Street West, Toronto, Ontario, Canada, M5X 1B1
Active Ingredients
BAMLANIVIMAB
700 MG / 20 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
6961cb2a408bfb4a
Type
Standard
Back to Health Canada Approvals